Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Saved in:
| Title: | Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. |
|---|---|
| Authors: | Bilgin, Burak1 (AUTHOR) drbbilgin@hotmail.com, Sendur, Mehmet Ali Nahit2 (AUTHOR), Yucel, Sebnem1 (AUTHOR), Celik, Emir3 (AUTHOR), Ozyukseler, Deniz Tataroglu4 (AUTHOR), Ayhan, Murat4 (AUTHOR), Basoglu, Tugba5 (AUTHOR), Ilhan, Aysegul6 (AUTHOR), Akdeniz, Nadiye7 (AUTHOR), Gulmez, Ahmet8 (AUTHOR), Dogan, Izzet9 (AUTHOR), Aktas, Burak Yasin10 (AUTHOR), Gurbuz, Mustafa11 (AUTHOR), Koca, Sinan12 (AUTHOR), Paydas, Semra13 (AUTHOR), Tatli, Ali Murat14 (AUTHOR), Cinkir, Havva Yesil15 (AUTHOR), Alan, Ozkan16 (AUTHOR), Erol, Cihan2 (AUTHOR), Hizal, Mutlu2 (AUTHOR) |
| Source: | Journal of Cancer Research & Clinical Oncology. Jul2021, Vol. 147 Issue 7, p2145-2152. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
